Dr Alyce L Garrity, MD | |
602 Chase Ave, Cordova, AK 99574-0160 | |
(907) 424-8000 | |
Not Available |
Full Name | Dr Alyce L Garrity |
---|---|
Gender | Female |
Speciality | Emergency Medicine |
Location | 602 Chase Ave, Cordova, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225062920 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 5228 (Alaska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Alyce L Garrity, MD Po Box 160, Cordova, AK 99574-0160 Ph: (907) 424-8000 | Dr Alyce L Garrity, MD 602 Chase Ave, Cordova, AK 99574-0160 Ph: (907) 424-8000 |
News Archive
University of Michigan researchers will use a new $1.6 million federal grant to probe potential social and environmental links to autism, collecting location-specific information from tens of thousands of affected individuals and their families nationwide.
Scientists are considering a third surge in COVID-19 incidence owing to the emergence of highly transmissible SARS-CoV-2 variants of concern (VOC). SARS-CoV-2 is the causal agent of the current COVID-19 pandemic. Some of these VOCs have been reported to have a rate of transmission much higher than the infectivity of the ancestral strain that had emerged in Wuhan, China, in 2019.
New evidence that women are more likely to be harmed than helped by screening tests for ovarian cancer is disturbing. The tests do nothing to prevent healthy women from dying from the usually fatal disease. Yet they often lead doctors to perform needless surgeries that cause serious complications in many patients.
Physician practices are engaging in new health care payment models intended to improve quality and reduce costs, but are finding that they need help with successfully managing increasing amounts of data and figuring out how to respond to the diversity of programs and quality metrics from different payers, according to a new joint study by the RAND Corporation and the American Medical Association.
Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Vancouver, British Columbia.
› Verified 9 days ago